Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Atossa Genetics, Inc. (ATOS) Starts Presentation at LD Micro Invitational Conference

Posted on June 7, 2016 by MissionIR

Atossa Genetics (NASDAQ: ATOS) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. The company’s leading pharmaceutical under development is Afimoxifene Topical Gel, or AfTG, which is in phase II clinical development. Atossa is also planning a phase II clinical trial using its patented intraductal Microcatheters to deliver fulvestrant to treat ductal carcinoma in-situ, or DCIS, and breast cancer. For more information, visit the company’s website at www.atossagenetics.com

The three-day LD Micro Invitational in Bel Air, California, features company presentations from more than 200 select high-potential small-cap companies spanning multiple industries. Institutional and retail investors in attendance also have access to numerous networking opportunities and social events to learn more about these companies. For more information on LD Micro, visit www.ldmicro.com
This entry was posted in LD Micro Conference. Bookmark the permalink.

Comments are closed.